FDA Approves Sandoz Inc ANDA for Rexulti Generic Brexpiprazole

The FDA approved Sandoz Inc’s ANDA for Brexpiprazole tablets, a generic version of Otsuka Pharmaceutical’s Rexulti.

• Brexpiprazole tablets between 0.25 mg and 4 mg approved
• “With this approval, Sandoz may be eligible for 180-days of shared generic drug exclusivity for Brexpiprazole Tablets”

NOTE

• Novartis AG rose 0.6% to CHF74.39 as of last close
  • The average 12-month price target of CHF90.20 is 21.3% above the current price
  • 17 buys, 12 holds, 4 sells

To view the source of this information, click here

To contact the reporter on this story:
Zac Fleming in New York at zfleming2@bloomberg.net

To contact the ...